Antibody and IFN-gamma responses induced by a recombinant canarypox vaccine and challenge infection with equine influenza virus.
In horses, equine influenza virus (EIV) is a leading cause of respiratory disease. Conventional inactivated vaccines induce a short-lived immune response. By comparison, natural infection confers a long-term immunity to re-infection. An aim of new equine influenza vaccines is to more closely mimic natural infection in order to achieve a better quality of immunity. A new live recombinant vaccine derived from the canarypox virus vector and expressing haemagglutinin genes of EIV (subtype H3N8) has been developed. Stimulation of the immune system was studied after immunisation with this canarypox-based vaccine and challenge infection by exposure to a nebulised aerosol of EIV. The humoral immune response was evaluated by measuring serum antibody levels using the single radial haemolysis (SRH) assay. The cellular immune response was assessed by the measurement of interferon gamma (IFN-gamma) synthesis in peripheral blood mononuclear cells (PBMC). Clinical signs of the disease (temperature, coughing, nasal discharge, dyspnoea, depression and anorexia) and virus excretion were monitored after challenge infection. Clinical signs and virus shedding were significantly reduced in vaccinates compared with unvaccinated controls. EIV-specific immunity was stimulated by vaccination with a recombinant vaccine as serological responses were detected after immunisation. This study also provided the first evidence for increased IFN-gamma protein synthesis in vaccinated ponies following challenge infection with EIV compared with control ponies.
Paillot
R
R
Animal Health Trust, Centre for Preventive Medicine, Lanwades Park, Newmarket, Suffolk CB8 7UU, UK. romain.paillot@aht.org.uk
Kydd
J H
JH
Sindle
T
T
Hannant
D
D
Edlund Toulemonde
C
C
Audonnet
J C
JC
Minke
J M
JM
Daly
J M
JM
D000818:Animals; D000914:Antibodies, Viral / Q000096:biosynthesis / Q000097:blood; D001831:Body Temperature / Q000276:immunology; D028121:Canarypox virus / Q000235:genetics / Q000276:immunology*; D006734:Horse Diseases / Q000276:immunology* / Q000821:virology*; D006736:Horses; D053123:Influenza A Virus, H3N8 Subtype / Q000276:immunology*; D007371:Interferon-gamma / Q000096:biosynthesis / Q000097:blood / Q000276:immunology; D007963:Leukocytes, Mononuclear / Q000276:immunology; D009976:Orthomyxoviridae Infections / Q000276:immunology / Q000517:prevention & control / Q000662:veterinary* / Q000821:virology; D014611:Vaccination / Q000662:veterinary*; D014614:Vaccines, Synthetic / Q000235:genetics / Q000276:immunology / Q000627:therapeutic use; D014765:Viral Vaccines / Q000235:genetics / Q000276:immunology* / Q000627:therapeutic use
D000914:Antibodies, Viral; D014614:Vaccines, Synthetic; D014765:Viral Vaccines; D007371:Interferon-gamma